Clinical Trials Browser

Completed × obinutuzumab × 90 days × Clear all

NCT04703686 2026-03-16

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Phase 2 Completed

Lymphoma, Mantle-Cell

NCT03332017 2026-02-18

ROSEWOOD

Phase 2 Completed

217 enrolled 23 charts 1 FDA

Lymphoma, Follicular

NCT02896582 2026-01-14

LyMa101

Phase 2 Completed

Lymphoma, Mantle-Cell